Dehydroxymethylepoxyquinomicin (DHMEQ) is primarily recognized for its potent anti-inflammatory and anticancer properties. It functions by inhibiting the activation of NF-κB, a transcription factor that plays a crucial role in regulating immune responses and cell survival. In research, DHMEQ is extensively used to study inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, as it effectively suppresses the production of pro-inflammatory cytokines. Additionally, its ability to block NF-κB activation makes it a promising candidate for cancer therapy, particularly in cases where NF-κB promotes tumor growth and resistance to chemotherapy. DHMEQ has also shown potential in neurodegenerative disease research, where inflammation contributes to disease progression. Its application in these areas highlights its significance as a tool for understanding and targeting inflammation-related pathways.